<DOC>
	<DOCNO>NCT00612274</DOCNO>
	<brief_summary>The primary objective trial study safety efficacy novel regimen sirolimus , tacrolimus methotrexate prophylaxis acute graft versus host disease ( GVHD ) recipient mismatch unrelated donor stem cell graft . Methotrexate administer low dose format 5mg/m2 day +1,3 6 .</brief_summary>
	<brief_title>Sirolimus , Tacrolimus Short Course Methotrexate Prevention Acute GVHD Recipients Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients must identify 8/10 9/10 match unrelated donor identify follow formal search confirmatory type national marrow donor program best available donor . No matched sibling fully match unrelated donor identify . HLA type donor recipient perform high resolution molecular typing HLA A , B , C DRB1/DQ locus . Patients whose best available donor match 8/10 locus must least one mismatch DQ locus . ( one mismatch HLA A , B , C , DR allow ) . Candidates trial meet follow criterion : 1 . Adequate organ function condition type : For patient receive ablative conditioning Left Ventricular ejection fraction &gt; 45 % DLCO &gt; 50 % Creatinine &lt; 1.5 Hepatic enzyme &lt; 3x upper limit normal . KPS &gt; 70 % For patient receive nonablative conditioning : KPS &gt; 70 % 2 . Patients follow disease consider eligible : AML first remission high risk feature ( poor risk cytogenetic abnormalities9 , persistent elevate blast count day +15 recovery marrow induction therapy ) . AML beyond first remission ALL first remission high risk feature ( ph+ , t4:11 ) ALL beyond first remission High risk Myelodysplasia ( RAEBII , RAEBI poorrisk cytogenetics ) Recurrent Aggressive NonHodgkins Hodgkins lymphoma ( indolent histology exclude ) fail autologous transplant inadequate response salvage therapy . CML transformation CLL transformation Fludarabine failure . Severe aplastic anemia recurrence failure immunosuppressive therapy . Prior allogeneic transplantation Active CNS leukemia . Female patient pregnant breast feed Karnofsky performance status &lt; 70 % . Active viral , bacterial fungal infection . Patients seropositive HIV 1,2 ; HTLV 1,2 ( due additional immunodeficiency induce transplantation immunosuppressive therapy ) Requirement antifungal prophylaxis Voriconazole first 30 day prohibit . Patients provide informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>allogeneic</keyword>
</DOC>